Scynexis (SCYX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$19.2M

Revenue (quarter)

$235,000.00

Revenue growth (year over year)

−82.77%

Gross profit (trailing twelve months)

$19.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$10.2M

Net income (quarter)

$7.4M

Net income growth (year over year)

+207.44%

Net margin

−53.26%

Return on equity

−18.38%

EPS (trailing twelve months)

−$0.91

Book value per share

$6.73

P/E (trailing twelve months)

—

Price to book

0.59

Debt to assets

10.72%

Payout ratio

—

Dividend yield

—

Company profile

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

• Is Scynexis (SCYX) profitable?

  No. Scynexis reported a net loss of $10.2M over the trailing twelve months.

• How much revenue does Scynexis (SCYX) make?

  Scynexis generated $19.2M in revenue over the trailing twelve months, down 82.77% year over year.

• How do I buy stock in Scynexis (SCYX)?

  SCYX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.